The DF/HCC Collaborative RNAi Core is pleased to announce the availability of three new miRNA-targeted libraries and a new laser scanning cytometer

Non-small cell lung cancer (NSCLC), the most commonly fatal malignancy in the United States, accounts for approximately 85 percent of all lung cancer

Most women with ovarian cancer are diagnosed in their 60s and 70s with advanced stage disease that has spread throughout the abdomen

The Recombinant Protein Expression and Purification (RPrEP) Core was launched in 2009 to provide a cost-effective resource to the DF/HCC community for expression and purification of recombinant fusion proteins necessary for pre-clinical studies as well as for basic mechanistic studies by immunologists and cancer biologists

The Tissue Microarray and Imaging Core is dedicated to the construction and evaluation of high quality tissue microarrays for cancer research

The Community Practice Core (CPC) offers access to a clinical laboratory of over ten million patients within Harvard Vanguard Medical Associates, Harvard Pilgrim Health Care, and the HMO Cancer Research Network

Twelve individuals have recently joined DF/HCC